Synergistic Anti-Mycobacterial Treatment Systems

The invention integrates oligo(carbamoylated guanidine) (OCG) compounds with distinct technologies, such as AI, IoT, blockchain, and new materials, to create a more powerful system for treating tuberculosis and monitoring treatment outcomes.

Tuberculosis (TB) is a deadly infectious disease caused by Mycobacterium tuberculosis (Mtb). The current TB treatment regimen is lengthy and rigorous due to difficulties associated with diagnosis, treatment, and patient monitoring. The original patent addressed this issue with OCG compounds, but the new inventive concept takes it a step further by synergistically combining these compounds with other technologies to create a more comprehensive and effective system.

The new system comprises an OCG-based pharmaceutical composition, an AI-powered diagnostic tool for identifying Mycobacterium tuberculosis strains, an IoT-enabled device for tracking patient response to treatment, and a blockchain-based platform for secure storage and analysis of patient data. The system also includes a novel material for wound dressings, comprising a composite of OCG and a nanofiber matrix, which exhibits synergistic antibacterial and wound-healing properties. Furthermore, the system incorporates an AI-powered predictive model for identifying high-risk TB patients and a blockchain-based platform for tracking TB treatment outcomes.

The new claims introduce a synergistic combination of OCG compounds with AI, IoT, blockchain, and new materials, which is not obvious from the original patent. The integration of these technologies provides a more comprehensive and effective system for treating TB and monitoring treatment outcomes, addressing the limitations of the original patent.

Alternative embodiments of the inventive concept could include using different AI algorithms for diagnostic and predictive purposes, incorporating other IoT-enabled devices for patient monitoring, or developing new materials with enhanced antibacterial properties. Variations of the system could also include integrating the OCG-based pharmaceutical composition with other treatment regimens or using the blockchain-based platform for tracking treatment outcomes in other diseases.

The synergistic anti-mycobacterial treatment system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in regions with high TB prevalence. The system's ability to provide a more comprehensive and effective treatment approach could lead to improved patient outcomes, reduced healthcare costs, and increased market share for pharmaceutical companies and healthcare providers.